Financial Performance - The company's fleet TCE (Time Charter Equivalent) / Operating Day was $51,156[7] - Spot TCE / Operating Day reached $52,464[7] - Fleet OpEx (excluding drydock) / Calendar Day was $10,094[7] - Net income for the three months ended June 30, 2023, was $51.72 million, compared to $24.85 million for the same period in 2022[24] - Net cash provided by operating activities was $63.27 million, compared to $34.09 million in the same period last year[24] Fleet Statistics - Fleet utilization was 98%[7] - Spot fleet utilization was 97.9%[7] Cash and Debt - Total cash and investments amounted to $155.6 million as of June 30, 2023[8] - Total debt obligations were $650.3 million[9] Market Trends - Global liftings increased by 8% Q/Q and 15% in 1H23[15] - U.S. waterborne exports increased by 2% Q/Q and 11% in 1H23[18] - Middle East waterborne exports increased by 15% Q/Q and 15% in 1H23[18] Environmental Initiatives - Scrubber vessel daily savings for calendar 2Q23 stood at $2,740/day net of all scrubber OPEX[23] - Average fuel differential for the last quarter was about $169.3/metric ton more for each ton of VLSFO vs each ton of HSFO supplied[23]

DORIAN LPG 1 Forward-Looking Statements Actual results could differ materially from expectations expressed in the forward-looking statements if one or more of the underlying assumptions or expectations proves to be inaccurate or is not realized. Our actual future results may be materially different from and worse than what we expect. We qualify all of the forward-looking statements by these cautionary statements. We caution readers of this presentation not to place undue reliance on forward-looking statemen ...

Capital Link Webinar January 2024 1 Disclaimer Forward-Looking Statements This presentation contains certain forward-looking statements including analyses and other information based on forecasts of future results and estimates of amounts not yet determinable and statements relating to our future prospects, developments and business strategies. Forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," ...

ServisFirst Bancshares, Inc. NYSE: SFBS March 2025 Forward-Looking Statements ▪ Statements in this presentation that are not historical facts, including, but not limited to, statements concerning future operations, results or performance, are hereby identified as "forward-looking statements" for the purpose of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. The words "believe," "expect," "anticipate," "project," "plan," "intend," ...

PSEG Investor Update Leading toward a sustainable future 1 March 2025 PSEG Investor Update March 2025 Forward-Looking Statements Certain of the matters discussed in this report about our and our subsidiaries' future performance, including, without limitation, future revenues, earnings, strategies, prospects, consequences, and all other statements that are not purely historical constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-loo ...

Vaxart's Oral Vaccine Platform - Vaxart's oral pill vaccines can revolutionize how the immune system responds and the way vaccines are delivered[8] - Vaxart's oral vaccine candidates have the potential to address many of the shortcomings of injectable vaccines, offering needle-free administration, mucosal and systemic immunity, potential to reduce transmission, benign safety & tolerability profile, thermostability, and self-administration[15] - Vaxart's proprietary VAAST® Platform utilizes mucosal immunity to generate IgA in addition to IgG to potentially block infection and transmission[18, 100] - Vaxart's oral platform drives broader immunity through mucosal IgA responses, offering greater cross-reactivity and potential for high variant coverage compared to injectable vaccines that only induce systemic IgG[31] Norovirus Vaccine Program - Norovirus is attributed to nearly one out of every five episodes of diarrheal disease globally[43] - Norovirus causes 685 million infections and 200,000 deaths worldwide annually, with economic costs of $60 billion[44] - The total potential market size for a Norovirus vaccine in the US is $3 – 5 billion[46] - Vaxart's bivalent Norovirus vaccine candidate is designed to address the major circulating genotypes, GI1 and GII4, with GII4 accounting for 68% of norovirus genotypes in the US from 2009-2015[53, 54] - In a Norovirus challenge study, Vaxart's oral tablet showed a 29% relative reduction in infection and a 21% relative reduction in Norovirus AGE, along with an 85% reduction in viral shedding[109, 111] COVID-19 and Influenza Vaccine Programs - Vaxart received a BARDA Project NextGen award of up to $460.7 million, with ~$240.1 million currently available for payment, to conduct a Phase 2b trial evaluating their COVID-19 vaccine candidate head-to-head against an approved mRNA comparator[69, 73, 95] - In a Phase 1 trial, 46% of participants that had increased IgA antibodies to SARS-CoV-2 S also had increased antibody responses to the S protein of other coronaviruses[78] - Vaxart's oral influenza vaccine candidate reduced infection rates by 49% compared to placebo and 38% compared to Fluzone in a human influenza challenge design[90]

Q3 2021 CONFIDENTIAL INVESTOR PRESENTATION Spring 2022 NASDAQ: PIK Disclaimer The information set forth herein contains statements that constitute "forward-looking statements" within the federal securities laws, including The Private Securities Litigation Reform Act of 1995, which provide a safe-harbor for forward-looking statements. In particular, when used in the preceding discussion, the words "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," ...

Financial Performance and Expectations - Acadia Pharmaceuticals expects to generate over $1 Billion in total U S revenues in 2025[12] - The company estimates a risk-adjusted peak sales potential of $25 Billion from its pipeline molecules[17] - The full potential peak sales for pipeline molecules is estimated at $12 Billion, assuming successful approval and commercialization[17] - Potential peak sales of current products are projected to be in the range of $15-$2 Billion[19] Pipeline Development and Strategy - Acadia Pharmaceuticals is focused on advancing care for underserved neurological and rare diseases[11] - The company has a late-stage pipeline with ACP-101 (P3-PWS) data expected in early Q4 2025 and ACP-204 (P2-ADP) data expected in mid-2026[12] - Acadia has 2 approved medicines and 9 disclosed and multiple undisclosed programs[30] - The company anticipates 7 Phase 2 or Phase 3 study starts in 2025 and 2026, and 5 Phase 2 or Phase 3 study readouts between 2025 and 2027[30] Key Programs and Indications - ACP-204 is being developed for Alzheimer's Disease Psychosis (ADP) and Lewy Body Dementia with Psychosis (LBDP), targeting approximately 3 million patients with psychosis across PDP, LBDP, and ADP in the US[45] - ACP-211 is in development for Major Depressive Disorder (MDD), a condition affecting approximately 21 million adults in the US[93, 125] - ACP-711 is being investigated for Essential Tremor (ET), which affects an estimated 7 million people or 22% of the US population[136, 171] - DAYBUE, approved for Rett syndrome, has seen >50% of patients remain on treatment at 12 months and 65% on treatment for 12+ months[271]

Company Overview - Reliance is a leading global diversified metal solutions provider with over 85 years of operational experience[7,8] - The company serves over 125,000 customers with over 100,000 metal products[8,16] - In 2024, approximately 50% of orders included value-added processing[14] Financial Performance - Reliance achieved EPS of $15.56 in 2024, the 4th highest level in its history[20] - In 2024, the company reported cash flow from operations of $1.43 billion, the 3rd highest in its history[23] - For Q1 2025, net sales were $3.48 billion[67] - Q1 2025 saw a gross profit margin of 29.7%[69] Capital Allocation and Stockholder Returns - Since 2020, Reliance has repurchased $3.20 billion of its common stock[50] - In Q1 2025, $253.2 million of share repurchases resulted in a 2% reduction in outstanding shares[50] - The company's capital expenditures since 2020 total $1.74 billion[52] Market Position and Growth - Reliance's U S tons sold represented approximately 15% of total Metals Service Center Institute shipments in 2024[93] - In Q1 2025, Reliance's year-over-year growth in shipments outperformed MSCI by 9.5%[58] - 2024 acquisitions contributed approximately $400 million of annualized net sales[111]

Improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Investor Presentation January 13, 2025 Disclaimer This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking ...